How does White Label Rx volume pricing work?

A volume model raises specific questions a clinic should resolve before signing. Ask whether your rate is tied to a minimum monthly commitment, what happens if you fall short of it, and whether better tiers require a contract term. Ask whether the negotiated rate is per SKU or blended across your order mix, since a strong rate on one drug can mask a weaker one on another. And ask whether rates reset or renegotiate over time, because a launch rate that drifts upward changes your margin math after you have already built patient pricing around it.

The harder issue with any unpublished volume model is verification. Without public tiers, you cannot independently check whether the rate you receive reflects the volume you bring. That is not a reason to dismiss the model — aggregated demand can genuinely lower cost — but it is a reason to get the curve in writing for your SKUs rather than relying on a general claim of volume savings.

Fizy Health prices the same compounded medications without putting cost behind a volume negotiation. It shows resolved per-vial 503A cost on each catalog and cart line before checkout, with a separately disclosed facilitation fee at payment. The drug cost passes through, so the number you see is the number you pay — visible whether you are a new clinic or a high-volume one, and visible before you commit to anything.

For clinics still scaling, that removes a chicken-and-egg problem: you do not need volume to see a competitive price, and you do not need to commit to a tier before you know your cost. You can compare a pass-through per-vial number against any White Label Rx volume quote on the exact SKUs you order most, and decide based on the landed number rather than the promise of a better tier later.